FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,723,372 | +17.5% | 362,053 | +40.7% | 0.06% | +6.6% |
| Q1 2023 | $1,467,180 | +55.5% | 257,400 | +175.3% | 0.06% | +22.0% |
| Q4 2022 | $943,304 | -53.5% | 93,489 | +3.3% | 0.05% | -36.7% |
| Q3 2022 | $2,028,000 | -11.2% | 90,510 | -1.7% | 0.08% | -20.2% |
| Q2 2022 | $2,283,000 | +25.2% | 92,120 | +95.9% | 0.10% | +25.3% |
| Q1 2022 | $1,824,000 | +2.2% | 47,018 | +56.1% | 0.08% | -38.8% |
| Q3 2021 | $1,785,000 | – | 30,121 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |